Women are increasingly using botanical dietary supplements (BDS) to reduce menopausal hot flashes. While licorice
(Glycyrrhiza sp.) is one of the frequently used ingredients in BDSs, the exact plant species is often not
identified. We previously showed that in breast epithelial cells (MCF-10A), Glycyrrhiza glabra (GG) and
G. inflata (GI), and their compounds differentially modulated P450 1A1 and P450 1B1 gene expression, which
are responsible for estrogen detoxification and genotoxicity, respectively. GG and isoliquiritigenin (LigC) increased CYP1A1,
whereas GI and its marker compound, licochalcone A (LicA), decreased CYP1A1 and CYP1B1. The objective of this study was to
determine the distribution of the bioactive licorice compounds, the metabolism of LicA and whether GG, GI,
and/or pure LicA modulate NAD(P)H quinone oxidoreductase (NQO1) in an ACI rat model. In addition, the effect of licorice extracts
and compounds on biomarkers of estrogen chemoprevention (CYP1A1) as well as carcinogenesis (CYP1B1) were studied. LicA was
extensively glucuronidated and formed GSH adducts; however, free LicA as well as LigC were bioavailable in target tissues after
oral intake of licorice extracts. GG, GI, and LicA caused induction of NQO1 activity in the liver. In mammary tissue, GI increased
CYP1A1 and decreased CYP1B1, whereas GG only increased CYP1A1. LigC may have contributed to the upregulation of CYP1A1 after GG
and GI administration. In contrast, LicA was responsible for GI-mediated downregulation of CYP1B1. These studies highlight the
polypharmacological nature of botanicals and the importance of standardization of licorice BDSs to specific
Glycyrrhiza species and to multiple constituents.